Patient Death Puts Trial on Hold for Universal CAR-T in Myeloma
The FDA issued a clinical hold for a trial evaluating a universal CAR T-cell product in patients with relapsed or refractory multiple myeloma after 1 patient died.
All articles by Christina Bennett, MS
Communication Style for Discussing Genetic Testing With Patients
The Consistent Testing Terminology Working Group selected plain language terminology that can be used when communicating with cancer patients about genetic testing.
New NCCN Patient Guidelines Feature Immunotherapy, CAR-T Side Effects
The NCCN recently released 2 sets of Guidelines for Patients that explain the side effects of different types of immunotherapies, such as CAR T-cell therapies.
Study Finds Higher Incidence of Atrial Fibrillation With Ibrutinib Therapy
Patients with chronic lymphocytic leukemia who are treated with ibrutinib may have a higher incidence of atrial fibrillation than previously thought.
First Guidelines for Providing Oncology Pharmacy Services in COVID-19
The first set of guidelines for providing oncology pharmacy services to cancer patients during the COVID-19 pandemic was recently published.
Study Links DLBCL and CLL Incidence to Race and Ethnicity, Urban Status
The incidence of DLBCL among Hispanic individuals and CLL among non-Hispanic black individuals was associated with urban status.
Real-World Outcomes for Patients With CLL Differ in Community Setting
The Connect CLL Registry revealed that real-world treatment outcomes for patients with CLL who were treated in the community setting differed from trial results.
FLAG+/-Ida Linked to Better Outcomes in Non-Favorable–Risk AML
Induction regimen FLAG+/-Ida appears to be more effective than 7+3 in patients with non-favorable risk AML, but prospective data are needed.
Second Hematologic Malignancy Deemed a “Rare” Event in CLL
The development of a second hematologic malignancy after being diagnosed with chronic lymphocytic leukemia (CLL) appears to be uncommon, a retrospective study found.
Study Calls for Unified Grading System for CAR-T Toxicities
A study found that grading systems for assessing toxicities from CAR-T therapy produced inconsistent scores, prompting a call for a more unified grading approach.
-
Loading...
-
Loading...
Next post in Leukemia
